Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints

SIMPLE SUMMARY: This review aims at analyzing an emergent topic regarding the possible combined use of poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi), anticancer drugs approved to treat tumors with defective repair of DNA damage, and immunostimulating agents, like Immune Checkpoint Inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Franzese, Ornella, Graziani, Grazia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688455/
https://www.ncbi.nlm.nih.gov/pubmed/36428727
http://dx.doi.org/10.3390/cancers14225633

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688455/
https://www.ncbi.nlm.nih.gov/pubmed/36428727
http://dx.doi.org/10.3390/cancers14225633

Ejemplares similares